Monte Rosa Therapeutics Stock (NASDAQ:GLUE)
Previous Close
$4.22
52W Range
$3.21 - $12.40
50D Avg
$5.76
200D Avg
$6.10
Market Cap
$271.26M
Avg Vol (3M)
$729.22K
Beta
1.53
Div Yield
-
GLUE Company Profile
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
GLUE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| FHTX | Foghorn Therapeutics Inc. |
| STOK | Stoke Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| NKTX | Nkarta, Inc. |
| NRIX | Nurix Therapeutics, Inc. |
| SANA | Sana Biotechnology, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| LYEL | Lyell Immunopharma, Inc. |
| KYMR | Kymera Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| IKNA | Ikena Oncology, Inc. |
| GBIO | Generation Bio Co. |
| STTK | Shattuck Labs, Inc. |